Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST) : a blinded, multicentre, randomised, controlled, phase 2 trial
Copyright © 2021 The Author(s). Published by Elsevier Ltd. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we investigated the reactogenicity and immunogenicity of seven different COVID-19 vaccines as a third dose after two doses of ChAdOx1 nCov-19 (Oxford-AstraZeneca; hereafter referred to as ChAd) or BNT162b2 (Pfizer-BioNtech, hearafter referred to as BNT).
METHODS: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of third dose booster vaccination against COVID-19. Participants were aged older than 30 years, and were at least 70 days post two doses of ChAd or at least 84 days post two doses of BNT primary COVID-19 immunisation course, with no history of laboratory-confirmed SARS-CoV-2 infection. 18 sites were split into three groups (A, B, and C). Within each site group (A, B, or C), participants were randomly assigned to an experimental vaccine or control. Group A received NVX-CoV2373 (Novavax; hereafter referred to as NVX), a half dose of NVX, ChAd, or quadrivalent meningococcal conjugate vaccine (MenACWY)control (1:1:1:1). Group B received BNT, VLA2001 (Valneva; hereafter referred to as VLA), a half dose of VLA, Ad26.COV2.S (Janssen; hereafter referred to as Ad26) or MenACWY (1:1:1:1:1). Group C received mRNA1273 (Moderna; hereafter referred to as m1273), CVnCov (CureVac; hereafter referred to as CVn), a half dose of BNT, or MenACWY (1:1:1:1). Participants and all investigatory staff were blinded to treatment allocation. Coprimary outcomes were safety and reactogenicity and immunogenicity of anti-spike IgG measured by ELISA. The primary analysis for immunogenicity was on a modified intention-to-treat basis; safety and reactogenicity were assessed in the intention-to-treat population. Secondary outcomes included assessment of viral neutralisation and cellular responses. This trial is registered with ISRCTN, number 73765130.
FINDINGS: Between June 1 and June 30, 2021, 3498 people were screened. 2878 participants met eligibility criteria and received COVID-19 vaccine or control. The median ages of ChAd/ChAd-primed participants were 53 years (IQR 44-61) in the younger age group and 76 years (73-78) in the older age group. In the BNT/BNT-primed participants, the median ages were 51 years (41-59) in the younger age group and 78 years (75-82) in the older age group. In the ChAd/ChAD-primed group, 676 (46·7%) participants were female and 1380 (95·4%) were White, and in the BNT/BNT-primed group 770 (53·6%) participants were female and 1321 (91·9%) were White. Three vaccines showed overall increased reactogenicity: m1273 after ChAd/ChAd or BNT/BNT; and ChAd and Ad26 after BNT/BNT. For ChAd/ChAd-primed individuals, spike IgG geometric mean ratios (GMRs) between study vaccines and controls ranged from 1·8 (99% CI 1·5-2·3) in the half VLA group to 32·3 (24·8-42·0) in the m1273 group. GMRs for wild-type cellular responses compared with controls ranged from 1·1 (95% CI 0·7-1·6) for ChAd to 3·6 (2·4-5·5) for m1273. For BNT/BNT-primed individuals, spike IgG GMRs ranged from 1·3 (99% CI 1·0-1·5) in the half VLA group to 11·5 (9·4-14·1) in the m1273 group. GMRs for wild-type cellular responses compared with controls ranged from 1·0 (95% CI 0·7-1·6) for half VLA to 4·7 (3·1-7·1) for m1273. The results were similar between those aged 30-69 years and those aged 70 years and older. Fatigue and pain were the most common solicited local and systemic adverse events, experienced more in people aged 30-69 years than those aged 70 years or older. Serious adverse events were uncommon, similar in active vaccine and control groups. In total, there were 24 serious adverse events: five in the control group (two in control group A, three in control group B, and zero in control group C), two in Ad26, five in VLA, one in VLA-half, one in BNT, two in BNT-half, two in ChAd, one in CVn, two in NVX, two in NVX-half, and one in m1273.
INTERPRETATION: All study vaccines boosted antibody and neutralising responses after ChAd/ChAd initial course and all except one after BNT/BNT, with no safety concerns. Substantial differences in humoral and cellular responses, and vaccine availability will influence policy choices for booster vaccination.
FUNDING: UK Vaccine Taskforce and National Institute for Health Research.
| Errataetall: |
ErratumIn: Lancet. 2021 Dec 18;398(10318):2246. - PMID 34922669 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:398 |
|---|---|
| Enthalten in: |
Lancet (London, England) - 398(2021), 10318 vom: 18. Dez., Seite 2258-2276 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Munro, Alasdair P S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B5S3K2V0G8 |
|---|
| Anmerkungen: |
Date Completed 03.01.2022 Date Revised 04.04.2024 published: Print-Electronic ErratumIn: Lancet. 2021 Dec 18;398(10318):2246. - PMID 34922669 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S0140-6736(21)02717-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334001110 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334001110 | ||
| 003 | DE-627 | ||
| 005 | 20240404233354.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0140-6736(21)02717-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM334001110 | ||
| 035 | |a (NLM)34863358 | ||
| 035 | |a (PII)S0140-6736(21)02717-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Munro, Alasdair P S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST) |b a blinded, multicentre, randomised, controlled, phase 2 trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2022 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Lancet. 2021 Dec 18;398(10318):2246. - PMID 34922669 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Elsevier Ltd. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we investigated the reactogenicity and immunogenicity of seven different COVID-19 vaccines as a third dose after two doses of ChAdOx1 nCov-19 (Oxford-AstraZeneca; hereafter referred to as ChAd) or BNT162b2 (Pfizer-BioNtech, hearafter referred to as BNT) | ||
| 520 | |a METHODS: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of third dose booster vaccination against COVID-19. Participants were aged older than 30 years, and were at least 70 days post two doses of ChAd or at least 84 days post two doses of BNT primary COVID-19 immunisation course, with no history of laboratory-confirmed SARS-CoV-2 infection. 18 sites were split into three groups (A, B, and C). Within each site group (A, B, or C), participants were randomly assigned to an experimental vaccine or control. Group A received NVX-CoV2373 (Novavax; hereafter referred to as NVX), a half dose of NVX, ChAd, or quadrivalent meningococcal conjugate vaccine (MenACWY)control (1:1:1:1). Group B received BNT, VLA2001 (Valneva; hereafter referred to as VLA), a half dose of VLA, Ad26.COV2.S (Janssen; hereafter referred to as Ad26) or MenACWY (1:1:1:1:1). Group C received mRNA1273 (Moderna; hereafter referred to as m1273), CVnCov (CureVac; hereafter referred to as CVn), a half dose of BNT, or MenACWY (1:1:1:1). Participants and all investigatory staff were blinded to treatment allocation. Coprimary outcomes were safety and reactogenicity and immunogenicity of anti-spike IgG measured by ELISA. The primary analysis for immunogenicity was on a modified intention-to-treat basis; safety and reactogenicity were assessed in the intention-to-treat population. Secondary outcomes included assessment of viral neutralisation and cellular responses. This trial is registered with ISRCTN, number 73765130 | ||
| 520 | |a FINDINGS: Between June 1 and June 30, 2021, 3498 people were screened. 2878 participants met eligibility criteria and received COVID-19 vaccine or control. The median ages of ChAd/ChAd-primed participants were 53 years (IQR 44-61) in the younger age group and 76 years (73-78) in the older age group. In the BNT/BNT-primed participants, the median ages were 51 years (41-59) in the younger age group and 78 years (75-82) in the older age group. In the ChAd/ChAD-primed group, 676 (46·7%) participants were female and 1380 (95·4%) were White, and in the BNT/BNT-primed group 770 (53·6%) participants were female and 1321 (91·9%) were White. Three vaccines showed overall increased reactogenicity: m1273 after ChAd/ChAd or BNT/BNT; and ChAd and Ad26 after BNT/BNT. For ChAd/ChAd-primed individuals, spike IgG geometric mean ratios (GMRs) between study vaccines and controls ranged from 1·8 (99% CI 1·5-2·3) in the half VLA group to 32·3 (24·8-42·0) in the m1273 group. GMRs for wild-type cellular responses compared with controls ranged from 1·1 (95% CI 0·7-1·6) for ChAd to 3·6 (2·4-5·5) for m1273. For BNT/BNT-primed individuals, spike IgG GMRs ranged from 1·3 (99% CI 1·0-1·5) in the half VLA group to 11·5 (9·4-14·1) in the m1273 group. GMRs for wild-type cellular responses compared with controls ranged from 1·0 (95% CI 0·7-1·6) for half VLA to 4·7 (3·1-7·1) for m1273. The results were similar between those aged 30-69 years and those aged 70 years and older. Fatigue and pain were the most common solicited local and systemic adverse events, experienced more in people aged 30-69 years than those aged 70 years or older. Serious adverse events were uncommon, similar in active vaccine and control groups. In total, there were 24 serious adverse events: five in the control group (two in control group A, three in control group B, and zero in control group C), two in Ad26, five in VLA, one in VLA-half, one in BNT, two in BNT-half, two in ChAd, one in CVn, two in NVX, two in NVX-half, and one in m1273 | ||
| 520 | |a INTERPRETATION: All study vaccines boosted antibody and neutralising responses after ChAd/ChAd initial course and all except one after BNT/BNT, with no safety concerns. Substantial differences in humoral and cellular responses, and vaccine availability will influence policy choices for booster vaccination | ||
| 520 | |a FUNDING: UK Vaccine Taskforce and National Institute for Health Research | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a ChAdOx1 nCoV-19 |2 NLM | |
| 650 | 7 | |a B5S3K2V0G8 |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Janani, Leila |e verfasserin |4 aut | |
| 700 | 1 | |a Cornelius, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Aley, Parvinder K |e verfasserin |4 aut | |
| 700 | 1 | |a Babbage, Gavin |e verfasserin |4 aut | |
| 700 | 1 | |a Baxter, David |e verfasserin |4 aut | |
| 700 | 1 | |a Bula, Marcin |e verfasserin |4 aut | |
| 700 | 1 | |a Cathie, Katrina |e verfasserin |4 aut | |
| 700 | 1 | |a Chatterjee, Krishna |e verfasserin |4 aut | |
| 700 | 1 | |a Dodd, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Enever, Yvanne |e verfasserin |4 aut | |
| 700 | 1 | |a Gokani, Karishma |e verfasserin |4 aut | |
| 700 | 1 | |a Goodman, Anna L |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Christopher A |e verfasserin |4 aut | |
| 700 | 1 | |a Harndahl, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Haughney, John |e verfasserin |4 aut | |
| 700 | 1 | |a Hicks, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a van der Klaauw, Agatha A |e verfasserin |4 aut | |
| 700 | 1 | |a Kwok, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Lambe, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Libri, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Llewelyn, Martin J |e verfasserin |4 aut | |
| 700 | 1 | |a McGregor, Alastair C |e verfasserin |4 aut | |
| 700 | 1 | |a Minassian, Angela M |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Mughal, Mehmood |e verfasserin |4 aut | |
| 700 | 1 | |a Mujadidi, Yama F |e verfasserin |4 aut | |
| 700 | 1 | |a Murira, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Osanlou, Orod |e verfasserin |4 aut | |
| 700 | 1 | |a Osanlou, Rostam |e verfasserin |4 aut | |
| 700 | 1 | |a Owens, Daniel R |e verfasserin |4 aut | |
| 700 | 1 | |a Pacurar, Mihaela |e verfasserin |4 aut | |
| 700 | 1 | |a Palfreeman, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Rampling, Tommy |e verfasserin |4 aut | |
| 700 | 1 | |a Regan, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Saich, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Salkeld, Jo |e verfasserin |4 aut | |
| 700 | 1 | |a Saralaya, Dinesh |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Sunil |e verfasserin |4 aut | |
| 700 | 1 | |a Sheridan, Ray |e verfasserin |4 aut | |
| 700 | 1 | |a Sturdy, Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Thomson, Emma C |e verfasserin |4 aut | |
| 700 | 1 | |a Todd, Shirley |e verfasserin |4 aut | |
| 700 | 1 | |a Twelves, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Read, Robert C |e verfasserin |4 aut | |
| 700 | 1 | |a Charlton, Sue |e verfasserin |4 aut | |
| 700 | 1 | |a Hallis, Bassam |e verfasserin |4 aut | |
| 700 | 1 | |a Ramsay, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Andrews, Nick |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen-Van-Tam, Jonathan S |e verfasserin |4 aut | |
| 700 | 1 | |a Snape, Matthew D |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xinxue |e verfasserin |4 aut | |
| 700 | 1 | |a Faust, Saul N |e verfasserin |4 aut | |
| 700 | 0 | |a COV-BOOST study group |e verfasserin |4 aut | |
| 700 | 1 | |a Riordan, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Ustianowski, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Rogers, Chris A |e investigator |4 oth | |
| 700 | 1 | |a Hughes, Stephen |e investigator |4 oth | |
| 700 | 1 | |a Longshaw, Laura |e investigator |4 oth | |
| 700 | 1 | |a Stockport, Jane |e investigator |4 oth | |
| 700 | 1 | |a Hughes, Rachel |e investigator |4 oth | |
| 700 | 1 | |a Grundy, Lynne |e investigator |4 oth | |
| 700 | 1 | |a Tudor Jones, Lona |e investigator |4 oth | |
| 700 | 1 | |a Guha, Arpan |e investigator |4 oth | |
| 700 | 1 | |a Snashall, Emma |e investigator |4 oth | |
| 700 | 1 | |a Eadsforth, Tom |e investigator |4 oth | |
| 700 | 1 | |a Reeder, Sally |e investigator |4 oth | |
| 700 | 1 | |a Storton, Kim |e investigator |4 oth | |
| 700 | 1 | |a Munusamy, Malathi |e investigator |4 oth | |
| 700 | 1 | |a Tandy, Bridget |e investigator |4 oth | |
| 700 | 1 | |a Egbo, Akamino |e investigator |4 oth | |
| 700 | 1 | |a Cox, Stephen |e investigator |4 oth | |
| 700 | 1 | |a Ahmed, Nabeela Nazir |e investigator |4 oth | |
| 700 | 1 | |a Shenoy, Anil |e investigator |4 oth | |
| 700 | 1 | |a Bousfield, Rachel |e investigator |4 oth | |
| 700 | 1 | |a Wixted, Donna |e investigator |4 oth | |
| 700 | 1 | |a Gutteridge, Helen |e investigator |4 oth | |
| 700 | 1 | |a Mansfield, Becky |e investigator |4 oth | |
| 700 | 1 | |a Herbert, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Holliday, Kyra |e investigator |4 oth | |
| 700 | 1 | |a Calderwood, James |e investigator |4 oth | |
| 700 | 1 | |a Barker, Dominique |e investigator |4 oth | |
| 700 | 1 | |a Brandon, Jacqueline |e investigator |4 oth | |
| 700 | 1 | |a Tulloch, Hayley |e investigator |4 oth | |
| 700 | 1 | |a Colquhoun, Suzie |e investigator |4 oth | |
| 700 | 1 | |a Thorp, Helen |e investigator |4 oth | |
| 700 | 1 | |a Radford, Helen |e investigator |4 oth | |
| 700 | 1 | |a Evans, Julie |e investigator |4 oth | |
| 700 | 1 | |a Baker, Helena |e investigator |4 oth | |
| 700 | 1 | |a Thorpe, Jeanette |e investigator |4 oth | |
| 700 | 1 | |a Batham, Sally |e investigator |4 oth | |
| 700 | 1 | |a Hailstone, Jessica |e investigator |4 oth | |
| 700 | 1 | |a Phillips, Rachael |e investigator |4 oth | |
| 700 | 1 | |a Kumar, Dileep |e investigator |4 oth | |
| 700 | 1 | |a Westwell, Fran |e investigator |4 oth | |
| 700 | 1 | |a Makia, Fiona |e investigator |4 oth | |
| 700 | 1 | |a Hopkins, NinaSimone |e investigator |4 oth | |
| 700 | 1 | |a Barcella, Lara |e investigator |4 oth | |
| 700 | 1 | |a Mpelembue, Mushiya |e investigator |4 oth | |
| 700 | 1 | |a Dabagh, Maja |e investigator |4 oth | |
| 700 | 1 | |a Lang, Matilda |e investigator |4 oth | |
| 700 | 1 | |a Khan, Farida |e investigator |4 oth | |
| 700 | 1 | |a Adebambo, Olumide |e investigator |4 oth | |
| 700 | 1 | |a Chita, Sunder |e investigator |4 oth | |
| 700 | 1 | |a Corrah, Tumena |e investigator |4 oth | |
| 700 | 1 | |a Whittington, Ashley |e investigator |4 oth | |
| 700 | 1 | |a John, Laurence |e investigator |4 oth | |
| 700 | 1 | |a Roche, Siobhan |e investigator |4 oth | |
| 700 | 1 | |a Wagstaff, Lynda |e investigator |4 oth | |
| 700 | 1 | |a Farrier, Adam |e investigator |4 oth | |
| 700 | 1 | |a Bisnauthsing, Karen |e investigator |4 oth | |
| 700 | 1 | |a Serafimova, Teona |e investigator |4 oth | |
| 700 | 1 | |a Nanino, Elisa |e investigator |4 oth | |
| 700 | 1 | |a Cooney, Enya |e investigator |4 oth | |
| 700 | 1 | |a Wilson-Goldsmith, Jaimie |e investigator |4 oth | |
| 700 | 1 | |a Nguyen, Hanna |e investigator |4 oth | |
| 700 | 1 | |a Mazzella, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Jackson, Beth |e investigator |4 oth | |
| 700 | 1 | |a Aslam, Suahil |e investigator |4 oth | |
| 700 | 1 | |a Bawa, Tanveer |e investigator |4 oth | |
| 700 | 1 | |a Broadhead, Samantha |e investigator |4 oth | |
| 700 | 1 | |a Farooqi, Sadaf |e investigator |4 oth | |
| 700 | 1 | |a Piper, Jo |e investigator |4 oth | |
| 700 | 1 | |a Weighell, Rowena |e investigator |4 oth | |
| 700 | 1 | |a Pickup, Lorinda |e investigator |4 oth | |
| 700 | 1 | |a Shamtally, Djamila |e investigator |4 oth | |
| 700 | 1 | |a Domingo, Jason |e investigator |4 oth | |
| 700 | 1 | |a Kourampa, Evgenia |e investigator |4 oth | |
| 700 | 1 | |a Hale, Colin |e investigator |4 oth | |
| 700 | 1 | |a Gibney, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Stackpoole, Michael |e investigator |4 oth | |
| 700 | 1 | |a Rashid-Gardner, Zalina |e investigator |4 oth | |
| 700 | 1 | |a Lyon, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a McDonnell, Chloe |e investigator |4 oth | |
| 700 | 1 | |a Cole, Christine |e investigator |4 oth | |
| 700 | 1 | |a Stewart, Anna |e investigator |4 oth | |
| 700 | 1 | |a McMillan, Gillian |e investigator |4 oth | |
| 700 | 1 | |a Savage, Mary |e investigator |4 oth | |
| 700 | 1 | |a Beckett, Helen |e investigator |4 oth | |
| 700 | 1 | |a Moorbey, Chantelle |e investigator |4 oth | |
| 700 | 1 | |a Desai, Amisha |e investigator |4 oth | |
| 700 | 1 | |a Brown, Claire |e investigator |4 oth | |
| 700 | 1 | |a Naker, Kush |e investigator |4 oth | |
| 700 | 1 | |a Qureshi, Ehsaan |e investigator |4 oth | |
| 700 | 1 | |a Trinham, Charlotte |e investigator |4 oth | |
| 700 | 1 | |a Sabine, Charlotte |e investigator |4 oth | |
| 700 | 1 | |a Moore, Sophie |e investigator |4 oth | |
| 700 | 1 | |a Hurdover, Steve |e investigator |4 oth | |
| 700 | 1 | |a Justice, Edwin |e investigator |4 oth | |
| 700 | 1 | |a Smith, David |e investigator |4 oth | |
| 700 | 1 | |a Plested, Emma |e investigator |4 oth | |
| 700 | 1 | |a Ferreira Da Silva, Carla |e investigator |4 oth | |
| 700 | 1 | |a White, Rachel |e investigator |4 oth | |
| 700 | 1 | |a Robinson, Hannah |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Lancet (London, England) |d 1945 |g 398(2021), 10318 vom: 18. Dez., Seite 2258-2276 |w (DE-627)NLM000473936 |x 1474-547X |7 nnns |
| 773 | 1 | 8 | |g volume:398 |g year:2021 |g number:10318 |g day:18 |g month:12 |g pages:2258-2276 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0140-6736(21)02717-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 398 |j 2021 |e 10318 |b 18 |c 12 |h 2258-2276 | ||